Tocofersolan
ALIMENTARY TRACT AND METABOLISM
Also known as: .ALPHA.-TOCOPHEROL, .ALPHA.-TOCOPHEROL, D-, .Alpha.-tocopherol, DL-, alpha-D-Tocopherol, alpha-tocopherol, ALPHA-TOCOPHEROL, D-, alpha-tocopherol, dl-, d-alpha-tocopherol, syntopherol, tocophersolan, vedrop
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Tocofersolan is an ofp drug catalogued in DrugCentral. DrugCentral lists 2 molecular targets, including GSTP1 and TTPA. Recorded indications include Obstruction of bile duct and Vitamin E deficiency.
- Approval status: ofp.
- Molecular targets: GSTP1 and TTPA (2 listed in DrugCentral).
- Indications: Obstruction of bile duct and Vitamin E deficiency.
- ATC code: A11HA08 (Other plain vitamin preparations).
- Molecular formula: C29H50O2; molecular weight 430.72 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Obstruction of bile duct
- Vitamin E deficiency
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Glutathione S-transferase P | GSTP1 | unknown | IC50 6.30 |
| Alpha-tocopherol transfer protein | TTPA | unknown | Kd 5.62 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| — | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A11HA08 | ALIMENTARY TRACT AND METABOLISM › VITAMINS › OTHER PLAIN VITAMIN PREPARATIONS › Other plain vitamin preparations |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Macular degeneration | 485.4 |
| Appendicolith | 268.7 |
| Therapy cessation | 241.0 |
| Blood uric acid increased | 232.4 |
| Blood phosphorus increased | 222.0 |
| Chronic sinusitis | 206.6 |
| Electric shock | 191.2 |
| Appendicitis | 181.7 |
| Paraesthesia oral | 168.1 |
| Vaginal flatulence | 164.6 |
| Procedural pain | 156.1 |
| Constipation | 151.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Tocofersolan is on its molecule page.
| Molecular formula | C29H50O2 |
|---|---|
| Molecular weight | 430.72 g/mol |
| CAS number | — |
| InChIKey | GVJHHUAWPYXKBD-IEOSBIPESA-N |
| PubChem CID | 14985 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Tocofersolan used for?
DrugCentral lists the following indications for Tocofersolan: Obstruction of bile duct and Vitamin E deficiency.
How does Tocofersolan work?
Its molecular targets in DrugCentral include GSTP1 and TTPA.
What is the chemical formula of Tocofersolan?
Tocofersolan has the molecular formula C29H50O2 and a molecular weight of 430.72 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4280 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2108106 — compound record and bioactivity
- PubChem CID 14985 — chemical identifiers
- DrugBank DB00163 — drug record
- FDA UNII N9PR3490H9 — substance identity
- DailyMed: FDA labels for Tocofersolan — current prescribing information (label search)
- UniProt P09211 (GSTP1) — target protein
- UniProt P49638 (TTPA) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.